Harrow, Inc. Deferred Tax Liabilities, Intangible Assets
Harrow, Inc. (HROW) had Deferred Tax Liabilities, Intangible Assets of $255.00 thousand as of 2021-12-31, per its 10-K filed 2023-03-23.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities
us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets · last filed 2023-03-23
- 2021-12-31: Deferred Tax Liabilities, Intangible Assets $255.00K.
- 2020-12-31: Deferred Tax Liabilities, Intangible Assets $274.00K.
- 2019-12-31: Deferred Tax Liabilities, Intangible Assets $270.00K.
| Period end | Deferred Tax Liabilities, Intangible Assets |
|---|---|
| 2021-12-31 | $255.00K 10-K · filed 2023-03-23 |
| 2020-12-31 | $274.00K 10-K · filed 2022-03-10 |
| 2019-12-31 | $270.00K 10-K · filed 2021-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |